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Treatment with a non-steroidal anti-inflammatory agent delays the growth
of spontaneous pulmonary metastases of a mammary adenocarcinoma of
non-detected immunogenicity
P.A. Fontan, C.R. Amura & D.O. Sordelli
Departamento de Microbiologia, Parasitologia e Inmunologia, Facultad de Medicina, Universidad de Buenos Aires, Argentina.
Summary Previous reports showed that treatment with non-steroidal anti-inflammatory agents (NSAIA) can
alter the growth profile of a variety of tumours. In this study, the effect of NSAIA treatment on the growth of
the primary tumour and the appearance of spontaneous pulmonary metastases, was investigated. A mammary
adenocarcinoma of non-detected immunogenicity, C7HI, was grafted subcutaneously in the lateral flank of
Balb/c mice. Oral treatment with -1 mg kg-' day-' piroxicam delayed both tumour growth and the growth
of pulmonary metastases. Survival of mice bearing the primary tumour was significantly lengthened by
anti-inflammatory treatment. Similarly, in separate experiments, after surgical removal of the primary tumour
by day 34 after grafting, the group of mice treated orally with piroxicam also exhibited a higher survival rate
than the control group. Upon surgical removal of the primary tumour 34 days after grafting, piroxicam
treatment significantly decreased both the number and size of pulmonary metastases. The results of this study
lends support to the hypothesis that inhibition or modulation of inflammation may delay tumour organisation
and growth. It is suggested that piroxicam treatment may be an appropriate adjunct therapy to delay the
appearance of pulmonary metastases and to increase life-expectancy in a host whose primary tumour has to be
surgically removed.
It is generally accepted that NSAIA treatment can alter the
in vivo growth profile of a variety of tumours. Significant
tumour regression was observed in patients with head and
neck carcinomas after treatment with NSAIA (Panje, 1981;
Hirsch et al., 1983). The fact that these and other cutaneous
carcinomas (Vanderveen et al., 1986) secrete prostaglandin E2
(PGE2) (El Attar & Lin, 1987), and that PGE2 acts as a
feedback inhibitor of cellular immune responses, which are
essential to anti-tumour immunity (Rolland et al., 1980;
Goodwin, 1984), may explain the action of NSAIA against
immunogenic tumours. Although the anti-tumoral activity of
NSAIA appears to be due, therefore, to restoration of
immune functions after PGE2 depletion, other mechanisms
may also intervene in growth inhibition of both immunogenic
and non-immunogenic tumours (Milas et al., 1990; Gelin et
al., 1991). This hypothesis is supported by the finding that
endogenously produced PGE2 does not seem to down-
regulate tumouricidal activity of macrophages (Utsugi &
Fidler, 1991).
An observation of significant medical importance is that
primary tumours growing as a single mass can inhibit the
growth of metastases (Prehn, 1991). Using a model of
artificial metastasis in the mouse, we have shown that
NSAIA treatment may mimic the inhibitory effect produced
by a primary tumour of non-detected immunogenicity
(Sordelli et al., 1989a). Because surgical removal of a primary
tumour is frequently followed by progression of multiple
metastases, and because patients usually die because metas-
tasis can be neither controlled nor eradicated, this study was
designed to determine whether piroxicam treatment inhibits
or delays in a murine model (i) the growth of a mammary
adenocarcinoma of non-detected immunogenicity, and (ii) the
development of spontaneous pulmonary metastases after ex-
perimental grafting and subsequent surgical removal of the
tumour.
Materials and methods
Animals
Male and female, 8-12 week old Balb/c mice were raised in
our animal house and under standard conditions and fed ad
libitum with Cargill (Buenos Aires) pelleted food and
acidified tap water (final concentration, 50 mM HCI,
pH = 2.8).
Tumour
C7HI is a metastatic mammary adenocarcinoma which was
induced in female Balb/c mice with medroxyprogesterone
acetate (Bonfil et al., 1989). C7HI cells are kept frozen under
liquid nitrogen and passaged subcutaneously (s.c.) in animals
for the experiments. A standard inoculum of the C7HI
tumour (-1 mm3), obtained from donor mice, was grafted
s.c. into the right lateral flank with the help of a trocar.
Tumour growth was evaluated by measuring the tumour size
with calipers, and the tumour volume (V in mm3) was deter-
mined using the formula: V = 0.4 x d2 x D. D and d repre-
sent the tumour longest and shortest diameters (Sordelli et
al., 1989a). In certain animals the primary tumour and sur-
rounding tissues were removed and evaluated macros-
copically to ascertain the degree of necrosis. Tumours were
also studied histopathologically throughout the experiments
by standard techniques.
Model ofmetastasis
The timetable for each experiment, i.e. the day the treatment
started, the day the primary tumour was excised and the day
mice were sacrificed, is given in each case. Mice were
sacrificed by cervical dislocation and the homolateral and
contralateral axillary lymph nodes were removed, and their
weight determined. In other experiments, mice were sacrificed
by pentobarbital overdose and the lungs were inflated in situ
with 10% buffered formalin and removed carefully. The
number of superficial metastases was determined with the
help ofmagnifying glasses (10 x). Metastases were arbitrarily
classified, according to their diameter, in four groups: (A)
4.5-3.5 mm, (B) 3.5-1.5 mm, (C) 1.5-0.5 mm, (D)
<0.5 mm. The approximate lung surface covered by metas-
tases (S) was obtained by the formula: S = [(NA x (4/
2)2 + NB X (2.5/2)2 + Nc X (1/2)2 + ND x (0.25/2)2]. N is the
number of metastases of each size range.
Piroxicam treatment
Piroxicam was obtained from Pfizer Laboratories, Buenos
Aires, Argentina. Piroxicam was dissolved in dimethylsulfox-
ide, diluted 1 to 10 in 0.1 N sodium bicarbonate and further
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diluted in 0.15 M NaCl to obtain the appropriate intra-
peritoneal (i.p.) doses or in tap water for oral dosage. Pirox-
icam doses for i.p. treatment ranged from 0.04 to
2.56 mg kg-'day-' piroxicam, whereas other mice received
-1 mg kg-' by the oral route with the drinking water (non-
acidified tap water). Wiseman (1973) and Otterness et al.
(1982) have shown that 1 mg kg-' given orally has potent
anti-inflammatory action, whereas mice treated over 18
months with 2, 4 and 8 mg kg-' developed dose-related gast-
rointestinal lesions and renal papillary necrosis (Wiseman,
1982). The starting point for piroxicam treatment is given in
Results for each experiment. The control group, in
experiments in which piroxicam was administered i.p., con-
sisted of mice injected daily with saline by the i.p. route.
Results
Considering the day the tumour was grafted as day 0 of the
experiment, treatment with 0.3 mg kg-' day-' piroxicam by
the i.p. route started on day -7, and mice were sacrificed on
day 98. Removal of the primary tumour by day 49 after
experimental grafting did not have any effect on lymph node
weight, measured on day 98 (Figure 1). Piroxicam treatment
alone diminished the homolateral lymph node weight by 38%
but, due to data dispersion, the difference was not significant.
Combined effect of tumour removal and anti-inflammatory
treatment, however, produced a significant decrease in lymph
node weight (Figure 1). Increase in lymph node weight is a
sign of invasion by C7HI cells. Histological analysis of
enlarged lymph nodes from mice bearing the C7HI tumour
revealed that the lymphoid tissue was almost totally replaced
by proliferative atypical cells with gland-like appearance, and
extensive areas of necrosis. The pathologist concluded, from
experiments carried out in double blind fashion, that lymph
nodes were metastasised by an anaplastic adenocarcinoma
(photomicrographs not shown). In separate experiments of
similar design, the primary tumour weight of mice treated
with piroxicam was decreased by -50% when compared
with that of untreated mice.
Piroxicam treatment inhibited the growth of C7HI pul-
monary metastases in a dose-related fashion (Figure 2). The
tumour was grafted on day 0, piroxicam i.p. treatment
started on day 26, tumours were removed on day 33 and
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Figure 1 The weight of homolateral axillary lymph nodes from
mice bearing the C7HI tumour. Piroxicam i.p. treatment started
on day - 7, the tumour was grafted on day 0, the primary
tumour was removed on day 49 and mice were sacrificed on day
98. Each bar represents the median of lymph node weight from
groups of 5 mice. (*) Significant difference, P = 0.029 (Rank Sum
test), when compared with groups receiving no NSAIA treat-
ment.
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Figure 2 Dose-response curve of the effect of piroxicam on
pulmonary metastasis growth. The tumour was grafted on day 0,
piroxicam i.p. treatment started on day 26, tumours were
removed on day 33 and mice were sacrificed on day 56. Each
point represents the median (n = 8) of the lung surface covered
by metastases in mice in which the primary tumour had been
surgically removed. Significant difference (*) P<0.02 (Rank sum
test).
mice were sacrificed on day 56. The total number of pul-
monary metastases was not significantly different, but metas-
tasis size was considerably reduced by anti-inflammatory
treatment. Because metastasis size was not uniform, metas-
tatic growth in the lung was expressed, therefore, as the
absolute area (mm2) of lung tissue covered by metastases.
Because parenteral treatment involved daily injections over
a long period of time, the efficacy of parenteral and oral
treatments were compared in several experiments. Both
parenteral treatment with 0.3-0.6 mg kg-' day-' and oral
treatment with -1 mg kg-' piroxicam given with the drink-
ing water induced inhibition of tumour growth and metas-
tasis development.
Piroxicam treatment significantly decreased the size of the
primary tumour. Piroxicam treatment started on day -7 of
the experiment with a daily oral dose of 1 mg kg-'. The
differences become apparent by day 27 after grafting and
remained significant throughout the experiment. Interest-
ingly, the degree of necrosis seen macroscopically in primary
tumours from mice treated with piroxicam was considerably
smaller than that of control mice (photographs not shown).
The last recording of tumour volume shown in Figure 3 was
made by day 86. After that day, increased mortality made
further tumour measurement in the small group of surviving
control mice meaningless. Survival of animals bearing the
C7HI tumour was significantly higher in mice subjected to
piroxicam oral treatment (Figure 4, top). In separate
experiments, after surgical removal of the primary tumour by
day 34 after grafting, the group of mice treated orally with
piroxicam also exhibited a higher survival rate than the
control group (Figure 4, bottom). In these experiments,
piroxicam treatment started on day - 7 with a daily oral
dose of 1 mg kg-', and the tumour was grafted on day 0.
The starting point of the experiments exhibited in Figure 4
were 4 months apart, and each experiment was repeated
twice.
The effect of combined piroxicam treatment and primary
tumour removal on pulmonary metastasis growth was
assessed in mice treated orally with -1 mg kg-' day-' of the
drug. The tumour was grafted on day 0, oral piroxicam
treatment started on day 21, the primary tumour was excised
on day 34 and mice were sacrificed on day 69. Removal of
the primary tumour did not modify significantly the number
of pulmonary metastases seen in untreated mice (Figure 5
top, groups 1 vs 2), whereas tumour removal decreased
significantly the number of pulmonary metastases in mice
under piroxicam treatment (Figure 5 top, groups 3 vs 4).
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Figure 3 Effect of oral piroxicam treatment on C7HI tumour
growth. Each point represents the median (n = 12) the tumour
volume in mice treated orally with -1 mg kg-' day-' piroxicam
and untreated control mice. Significant differences with (*)
P<0.01, and (**) P<0.001 (Rank sum test).
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Figure 4 Survival of mice treated orally with
- l mg kg-' day-'
piroxicam and untreated control mice. The effect of piroxicam
treatment on mice bearing the primary tumour is depicted on the
top panel. Each point represents the median (n = 12) of mouse
survival (%) up to day 215 after tumour grafting. Differences
between both groups became significant by day 109 (P = 0.0135)
and remained significant until day 166 (P = 0.0466). Levels of
significance (Fisher's test) varied from 0.0498 (day 118) to 0.0061
(day 133). The chart on the bottom panel shows the combined
effect of piroxicam oral treatment and surgical removal of the
primary tumour on mouse survival. Each point represents the
median (n = 19) of mouse survival (%). Differences between both
groups became significant by day 111 (P = 0.0380) and rem-
nained significant until day 152 (P = 0.0044). Levels of
significance (Fisher's test) varied from 0.0380 (day 111) to 0.0005
(day 120).
Maximum effect of treatment was observed in mice in which
the primary tumour was removed. These data show that
NSAIA had a synergistic inhibitory effect with the tumour
removal on the total number of metastases (Figure 5 top,
groups 1 vs 4). Dispersion of data from group 2 was con-
sistently high and, although the total number of metastases
was considerable decreased in group 4, when compared with
group 2, the difference was statistically not significant. Deter-
mination of the lung surface covered by metastases confirmed
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Figure 5 The effect of oral treatment with 1 mg kg-' day-'
piroxicam on C7HI tumour metastatic growth in the lungs. The
tumour was grafted on day 0, oral piroxicam treatment started
on day 21, the primary tumour was excised on day 34 and mice
were sacrificed on day 69. Each bar represents the median from
10-12 mice. The diagram on the top shows the total number of
metastases found on the surface of both lungs, and the bottom
one shows the lung surface covered by metastases. Significant
differences were: (top) groups 1 vs 4: P<0.001; 2 vs 4: P>0.05; 3
vs 4: P<0.001; (bottom): 1 vs 4: P<0.001; 2 vs 4: P<0.05; 3 vs
4: P<0.002 (Rank Sum test). All other differences were not
significant.
the observation made through determination of the total
number of metastases, in spite of their difference in size
(Figure 5, bottom). Piroxicam treatment in mice in which the
primary tumour had been removed significantly decreased the
pulmonary area covered by metastases (groups 2 vs 4). This
finding suggests that piroxicam delayed the development of
metastases, and kept them at the small size stage. This was
observed in every experiment in which metastasis size was
compared between groups of treated and untreated mice
(data not shown).
Discussion
The effect of the treatment with NSAIA on the growth of
different types of neoplasias has been investigated in human
beings and in a variety of animal models. Only a few studies,
however, addressed the role of these agents in the control of
metastases (Kort et al., 1986; Fisher et al., 1989; Fulton et
al., 1991). In this report, we showed that oral treatment of
mice with piroxicam delays the growth of spontaneous pul-
monary metastases of a mammary adenocarcinoma of non-
detected immunogenicity, upon surgical removal of the
primary tumour. Furthermore, survival of mice, with or
without removal of the primary tumour, was significantly
lengthened by anti-inflammatory treatment. NSAIA action
on metastasis development can occur at least at two different
stages: (i) neoplastic cell spreading from the primary tumour
and (ii) incipient metastasis growth, which requires neovas-
cularisation.
The mechanism of action of piroxicam in this study was
not investigated and can only be presumed on the basis of
previous data. Although the tumour used in this study is
weakly immunogenic or non-immunogenic, enhancement of
cell-mediated immunity against the tumour associated to
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reduction of prostaglandin E2 synthesis cannot be ignored
(Lau et al., 1987; Pollard, 1989). The observed anti-tumour
effect might also be explained on a non-immunological basis.
The stimuli that promote tumour angiogenesis may be pro-
vided directly by the tumour cells or indirectly by host
inflammatory cells that are attracted to the tumour site
(Young & Newby, 1986; Young et al., 1987; Folkman, 1990).
Prostaglandins El and E2 have been shown to be powerful
stimuli for tumour angiogenesis (Blood & Zetter, 1990).
Therefore, inhibition of prostaglandin synthesis by piroxicam
may lead to decreased angiogenesis and consequent inhibi-
tion of tumour growth. It may be speculated that the drug
inhibited the formation of or dilatation of tumour blood
vessels, thus reducing either tumour metabolism or the escape
of malignant cells into the circulation.
NSAIAs have been shown to inhibit the induction of
ornithine-decarboxylase activity (Verma et al., 1980). Because
increased levels of that enzyme and of polyamines have been
observed in tumour promotion (Boutwell, 1983), piroxicam
may have acted by inhibiting the enzyme thus abolishing
tumour promotion. It could also be speculated that pirox-
icam may have acted through a direct cytotoxic effect on the
C7HI tumour cells. Although we have not tested this, there is
previous evidence that other potent NSAIA causes no direct
effect on cultured tumour cells (Gelin et al., 1991).
Furthermore, piroxicam clearly affects migration of cells,
especially polymorphonuclear leukocytes (Sordelli et al.,
1989b), and these cells are known to be involved at several
stages of tumour development. In this regard, Aeed et al.
(1988) have shown that neutrophils may play an activating
role in tumour growth and metastatic potential of mammary
adenocarcinoma cells. There is general agreement that cells of
the acute inflammatory response that are attracted to the
tumour site (Fu et al., 1992), e.g. neutrophils and monocytes,
are directly involved in acute tissue damage (Lichtenstein,
1987). Reactive oxygen species and lysosomal enzymes
released by these cells can cause extracellular matrix destruc-
tion at the tumour periphery, thus facilitating tumour cell
shedding and successful metastatic dissemination (Blood &
Zetter, 1990). It may be speculated that modulation of
granulocyte margination at the primary tumour would
diminish tissue damage thus hampering tumour cell
spreading and production of, as seen in this report, lymph
node and pulmonary metastasis. In this study, we showed
decreased tissue damage and necrosis in primary C7HI
tumours of mice treated with piroxicam, when compared
with control mice without anti-inflammatory treatment. Our
findings suggest that piroxicam not only limits the growth of
the source of tumour cells able to produce metastases, i.e. the
primary tumour, but also may hinder the passage of these
cells to the lymphatics by lessening tissue damage at the site
of primary tumour growth.
Leukocytes also play an important role at sites other than
the primary tumour, through the process of arrest and ext-
ravasation of tumour cells (Killion & Fidler, 1989). In fact,
other authors showed an increase in pulmonary metastases
after oxygen radical and degradative enzyme damage of
endothelial cells, which facilitates the passage of tumour cells
into the extravascular space (Orr & Warner, 1987; Liotta,
1986). The extravasation of tumour cells to the extravascular
tissue space has much in common with the inflammatory
process. The fact that piroxicam treatment decreases migra-
tion of PMNL towards an inflammatory stimulus in the
lungs (Sordelli et al., 1989b) lends support to the hypothesis
that the NSAIA mode of action may also be related to
amelioration of inflammatory cell migration to the site of
incipient tumour. Whether piroxicam treatment decreases
margination of tumour cells into the lungs is not known and
merits further investigation.
In conclusion, we have shown that piroxicam treatment
retards metastasis growth after removal of a mammary
adenocarcinoma of non-detected immunogenicity, and inc-
reases the life expectancy of a host bearing the tumour.
Because only piroxicam was tested in this study, it would be
desirable to ascertain whether other NSAIA are able to
inhibit the growth of the C7HI tumour. Because the
effectiveness of the treatment may depend not only on the
host but also on the intrinsic characteristics of the non-
immunogenic tumour, further studies are required to ascer-
tain which tumours would be effectively inhibited by treat-
ment with agents that modulate inflammation.
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